Gardner Lewis Asset Management L P Lowers Holdings in Humana Inc. (NYSE:HUM)

Gardner Lewis Asset Management L P reduced its position in shares of Humana Inc. (NYSE:HUM) by 56.3% in the fourth quarter, Holdings Channel reports. The firm owned 9,670 shares of the insurance provider’s stock after selling 12,445 shares during the period. Gardner Lewis Asset Management L P’s holdings in Humana were worth $2,453,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HUM. Orion Portfolio Solutions LLC boosted its stake in Humana by 3.7% during the fourth quarter. Orion Portfolio Solutions LLC now owns 4,834 shares of the insurance provider’s stock valued at $1,226,000 after buying an additional 171 shares during the period. denkapparat Operations GmbH bought a new position in Humana in the 4th quarter worth about $323,000. Pictet Asset Management Holding SA raised its holdings in shares of Humana by 18.8% in the 4th quarter. Pictet Asset Management Holding SA now owns 72,803 shares of the insurance provider’s stock valued at $18,471,000 after acquiring an additional 11,523 shares in the last quarter. High Ground Investment Management LLP boosted its position in shares of Humana by 43.5% during the 4th quarter. High Ground Investment Management LLP now owns 424,403 shares of the insurance provider’s stock valued at $107,675,000 after acquiring an additional 128,636 shares during the last quarter. Finally, New Age Alpha Advisors LLC purchased a new position in shares of Humana during the fourth quarter worth about $2,960,000. Institutional investors own 92.38% of the company’s stock.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the sale, the insider now owns 8,181 shares in the company, valued at $2,096,463.06. The trade was a 31.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.37% of the company’s stock.

Humana Trading Down 0.2 %

Shares of HUM opened at $270.04 on Friday. The stock has a market capitalization of $32.59 billion, a P/E ratio of 27.14, a PEG ratio of 2.05 and a beta of 0.57. Humana Inc. has a twelve month low of $213.31 and a twelve month high of $406.46. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.68. The firm has a fifty day simple moving average of $270.51 and a two-hundred day simple moving average of $274.93.

Humana (NYSE:HUM) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, research analysts anticipate that Humana Inc. will post 16.47 EPS for the current year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be given a $0.885 dividend. The ex-dividend date is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.31%. Humana’s dividend payout ratio is currently 35.58%.

Wall Street Analyst Weigh In

HUM has been the subject of several research analyst reports. Royal Bank of Canada reiterated an “outperform” rating and set a $283.00 target price on shares of Humana in a research report on Wednesday, February 12th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $290.00 price objective on shares of Humana in a report on Wednesday, February 12th. Barclays upped their target price on shares of Humana from $255.00 to $270.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 13th. Morgan Stanley lowered their price target on Humana from $301.00 to $285.00 and set an “equal weight” rating on the stock in a research report on Wednesday, February 12th. Finally, Piper Sandler upped their price objective on Humana from $270.00 to $288.00 and gave the stock a “neutral” rating in a report on Wednesday, January 15th. Eighteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $285.68.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.